Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant for acute conversion of atrial fibrillation in critically ill ICU patients
NL-OMON41549Suspended
- Sponsor
- Isala
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vernakalant and amiodarone in Atrial fibrillation (AFib) (4 arms), sponsored by Isala. Primary endpoint: Conversion to sinus rhythm within 90 minutes. Started Jan 2014; status: suspended.
02
Drugs
vernakalantamiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON41549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41549.